[Bio CEO Interview] RudaCure CEO Yongho Kim pursues active 联合研究 with 翰林制药, including RCI001 Phase 1 临床试验, to overcome the limitations of 生物风投企业s
http://www.medigatenews.com/news/2535905009
"Securing diverse 管线s beyond 干眼症 to establish ourselves as a company that overcomes 生物风投企业 limitations"
RudaCure's 研发 管线 — including RCI001 as well as 疼痛治疗药 RCI002, 特应性皮炎 treatment RCI003, metastatic cancer treatment RCI004, and AMD/age-related 黄斑变性 treatment RCI005 — consists entirely of treatments for 感觉障碍 related to quality of life.
RCI002 is planned to undergo pre临床试验 this year, with DS/DP production in the following year, and Phase 1 临床试验 in 2023. Currently, in vitro 疗效 studies are underway.